Related Experiment Videos
Combination therapy in experimental invasive aspergillosis
D George1, D Kordick, P Miniter
1Yale University School of Medicine, Dept. of Medicine, New Haven, CT 06510.
The Journal of Infectious Diseases
|September 1, 1993
Summary
Combination antifungal therapy, including fluconazole and amphotericin B, prolonged survival in a rabbit model of invasive aspergillosis. High-dose amphotericin B was most effective, with no antagonism observed in combined treatments.
Area of Science:
- Medical Mycology
- Infectious Diseases
- Pharmacology
Background:
- Invasive aspergillosis is a serious fungal infection, particularly in immunocompromised individuals.
- Optimal antifungal treatment strategies, especially combination therapies, require further investigation.
Purpose of the Study:
- To evaluate the efficacy of combination antifungal therapy against invasive aspergillosis.
- To assess potential antagonism between fluconazole, amphotericin B, and flucytosine.
Main Methods:
- An immunosuppressed rabbit model was used to study invasive aspergillosis.
- Animals were treated with fluconazole, amphotericin B, or combinations thereof.
- Survival rates and mortality were monitored following challenge with Aspergillus fumigatus.
Main Results:
- Combination therapy with fluconazole and amphotericin B prolonged survival.
- High-dose amphotericin B demonstrated the highest efficacy.
- No antagonism was observed between fluconazole and amphotericin B, or flucytosine and amphotericin B, or fluconazole and flucytosine.
Conclusions:
- Combination antifungal therapies, including fluconazole and amphotericin B, are not antagonistic.
- High-dose amphotericin B is a highly effective treatment for invasive aspergillosis.
- Findings may inform human treatment strategies for invasive aspergillosis.